0001852647-26-000002.txt : 20260605 0001852647-26-000002.hdr.sgml : 20260605 20260605170238 ACCESSION NUMBER: 0001852647-26-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260605 DATE AS OF CHANGE: 20260605 EFFECTIVENESS DATE: 20260605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Spine BioPharma, Inc. CENTRAL INDEX KEY: 0001852647 ORGANIZATION NAME: EIN: 831212524 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-586448 FILM NUMBER: 261070117 BUSINESS ADDRESS: STREET 1: 505 PARK AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212-583-9700 MAIL ADDRESS: STREET 1: 505 PARK AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: Spine BioPharma, LLC DATE OF NAME CHANGE: 20210322 D 1 primary_doc.xml X0708 D LIVE 0001852647 Spine BioPharma, Inc. 505 PARK AVENUE, 14TH FLOOR NEW YORK NY NEW YORK 10022 212-583-9700 DELAWARE Spine BioPharma, LLC Corporation true Marc R. Viscogliosi 505 Park Avenue, 14th Floor New York NY NEW YORK 10022 Executive Officer Director Director and Chief Executive Officer of the Issuer Fran Magee 505 Park Avenue, 14th Floor New York NY NEW YORK 10022 Executive Officer Chief Technology Officer Thomas Bumol, PhD 505 Park Avenue, 14th Floor New York NY NEW YORK 10022 Director Frank Cammisa, MD 505 Park Avenue, 14th Floor New York NY NEW YORK 10022 Director John J. Viscogliosi 505 Park Avenue, 14th Floor New York NY NEW YORK 10022 Director Pharmaceuticals Decline to Disclose 06b false 2026-05-22 false true false 0 8500000 384798 8115202 false 3 0 0 0 false Spine BioPharma, Inc. /s/ Marc R. Viscogliosi Marc R. Viscogliosi Chief Executive Officer 2026-06-05